NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Recommendation of “Moderate Buy” by Brokerages

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nine have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $49.7273.

NAMS has been the subject of a number of recent analyst reports. Jefferies Financial Group reiterated a “buy” rating and set a $45.00 price target on shares of NewAmsterdam Pharma in a report on Monday, July 20th. Royal Bank Of Canada decreased their price objective on shares of NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, BMO Capital Markets initiated coverage on shares of NewAmsterdam Pharma in a report on Monday, July 20th. They set an “outperform” rating and a $58.00 target price for the company.

Insider Buying and Selling

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 105,000 shares of the company’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the completion of the transaction, the chief accounting officer owned 24,353 shares of the company’s stock, valued at $738,870.02. This represents a 81.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 12.74% of the stock is owned by insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds have recently made changes to their positions in NAMS. Frazier Life Sciences Management L.P. boosted its holdings in NewAmsterdam Pharma by 6.8% in the second quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company’s stock valued at $613,033,000 after acquiring an additional 1,145,128 shares in the last quarter. Capital World Investors raised its holdings in NewAmsterdam Pharma by 1.6% in the 4th quarter. Capital World Investors now owns 9,984,000 shares of the company’s stock worth $350,239,000 after purchasing an additional 161,289 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of NewAmsterdam Pharma by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after purchasing an additional 697,129 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in shares of NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after purchasing an additional 1,062,359 shares during the period. Finally, Polar Capital Holdings Plc boosted its stake in shares of NewAmsterdam Pharma by 15.6% during the 3rd quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock valued at $82,807,000 after purchasing an additional 393,855 shares in the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Price Performance

Shares of NAMS stock opened at $26.85 on Tuesday. The business has a 50-day moving average of $30.58 and a 200 day moving average of $32.11. NewAmsterdam Pharma has a 1-year low of $23.05 and a 1-year high of $42.21. The stock has a market capitalization of $3.21 billion, a PE ratio of -12.43 and a beta of 0.10.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The company had revenue of $3.70 million during the quarter, compared to the consensus estimate of $2.83 million. NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. Analysts anticipate that NewAmsterdam Pharma will post -1.82 EPS for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.